- In February 2026, Twist Bioscience Corporation announced it had entered a licensing agreement with Invenra Inc., becoming co-exclusive provider of Invenra’s B-Body bispecific antibody platform and extending its antibody discovery services, in exchange for US$5,000,000 in cash, US$15,000,000 in common stock, and an additional US$13,800,000 stock-funded preferred stake of about 6% in Invenra.
- By securing rights to Invenra’s bispecific antibody technology and all associated discovery and license revenue while paying Invenra a 20% royalty on license income, Twist is deepening its role as a wet lab and AI-enabled discovery partner across biologics workflows.
- Next, we’ll examine how adding co-exclusive access to Invenra’s B-Body bispecific antibody platform could influence Twist Bioscience’s broader investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Twist Bioscience Investment Narrative Recap
To own Twist Bioscience, you generally need to believe its synthetic DNA, NGS, and biologics platforms can scale into a larger, more diversified revenue base despite ongoing losses. The Invenra deal modestly reinforces the near term catalyst of expanding higher value biologics services, but it does not directly resolve the key risk of continued negative EBITDA and potential dilution if cash needs rise.
The most relevant recent announcement here is Twist’s February 2026 guidance raise, calling for full year revenue of US$435–US$440 million, about 16% growth at the midpoint. Against that backdrop, adding co exclusive access to bispecific antibody discovery slots naturally into the same story of product breadth and higher margin workflows, even as customer concentration and margin sustainability remain important watchpoints.
Yet while this expansion looks promising, investors should also be aware of how ongoing losses could still force Twist to seek fresh capital and...
Read the full narrative on Twist Bioscience (it's free!)
Twist Bioscience's narrative projects $575.2 million revenue and $92.4 million earnings by 2028. This requires 16.7% yearly revenue growth and about a $177.6 million earnings increase from -$85.2 million today.
Uncover how Twist Bioscience's forecasts yield a $35.62 fair value, a 27% downside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts paint a much harsher picture, assuming roughly US$556 million revenue and US$90 million earnings by 2028, so if you worry about rising R&D costs and squeezed margins, it is worth comparing that more cautious view with how the Invenra deal might reshape Twist’s long term profit potential.
Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth as much as 19% more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.
Ready For A Different Approach?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Find 54 companies with promising cash flow potential yet trading below their fair value.
- Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com